Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer

This study has been completed.
Sponsor:
Collaborators:
Mount Sinai School of Medicine
Beth Israel Medical Center
St. Luke's-Roosevelt Hospital Center
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00142506
First received: August 31, 2005
Last updated: April 23, 2014
Last verified: April 2014

August 31, 2005
April 23, 2014
February 2005
April 2014   (final data collection date for primary outcome measure)
  • Determine if prophylactic sildenafil citrate used before, during & after course of radiotherapy (external beam radiotherapy &/or brachytherapy w or w/o hormone therapy) can prevent loss of spontaneous erectile function 2 yrs from start of radiation tx. [ Time Frame: 2 years from start of RT ] [ Designated as safety issue: No ]
  • Diminish the time to restoration of erectile function for the study population. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
To determine if prophylactic sildenafil citrate used before, during and after a course of radiotherapy (external beam radiotherapy or brachytherapy) can prevent loss of spontaneous erectile function 2 yrs from the start of radiation treatment.
Complete list of historical versions of study NCT00142506 on ClinicalTrials.gov Archive Site
  • To determine if the prophylactic use of sildenafil citrate during radiotherapy may improve the long-term response to the drug following treatment [ Time Frame: 2 years from start of RT ] [ Designated as safety issue: No ]
  • To determine if sildenafil citrate used during a course of external beam radiotherapy or brachytherapy among patients will reduce acute and late urinary effects of radiotherapy. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • To determine the impact of dosimetry and radiation exposure to both the neurovascular bundle and bulb of the penis on erectile function preservation in the study population undergoing brachytherapy. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • To assess the impact on quality of life following prophylactic and on demand Sildenafil utilization in the study population. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • To determine the relationship between testosterone levels, erectile function and efficacy of prophylactic and on demand Sildenafil utilization in the study population. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
To determine if the prophylactic use of sildenafil citrate during radiotherapy may improve the long-term response to the drug following treatment.
Not Provided
Not Provided
 
Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer
This Protocol is a Randomized Prospective Study Comparing Prophylactic and on Demand Sildenafil Citrate Usage Administered During and After Radiotherapy With or Without Hormone Therapy Versus Radiotherapy With or Without Hormone Therapy Alone for the Preservation of Erectile Function After Therapy for Potent Patients With Clinically Localized Prostate Cancer

Radiation sometimes affects the ability for a person to have a normal erection. Complete loss of erections after radiation treatment can happen in 40-50% of treated patients. There are medications, like sildenafil (also known as Viagra), that can help the ability to get back erections in almost 70% of such patients.

The purpose of this study is to see if taking Viagra every day starting right before, during and for about 6 months after treatment, could reduce the risk of long-term erectile dysfunction.

This protocol is a randomized prospective study comparing prophylactic and on demand Sildenafil Citrate usage administered during and after radiotherapy in combination with or without hormone therapy versus radiotherapy alone for the preservation of erectile function in potent patients with clinically localized prostate cancer. The primary objectives of this protocol are to determine if prophylactic and on demand usage of Sildenafil Citrate can preserve spontaneous erectile function as well as diminish the time to restoration of erectile function in potent men receiving radiotherapy with or without hormone therapy for localized prostate cancer. Secondary objectives of this study are: to determine whether prophylactic and on demand use of Sildenafil Citrate during therapy may improve the long-term response to the drug following treatment; to determine whether prophylactic and on demand use of Sildenafil Citrate during therapy will reduce acute and late urinary effects of radiotherapy; to determine the impact of dosimetry and radiation exposure to both the neurovascular bundle and bulb of the penis on erectile function preservation in the study population undergoing brachytherapy and hormone therapy; to asses the impact on quality of life following prophylactic and on demand Sildenafil Citrate usage in the study population; to determine the relationship between testosterone levels, erectile function and efficacy of prophylactic and on demand Sildenafil Citrate usage in the study population.

Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
  • Prostate Cancer
  • Erectile Dysfunction
  • Drug: sildenafil citrate and questionaires

    Hormone therapy patients will be instructed to begin the study drug simultaneously or within 1 month of start of hormone therapy. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand open label, flexible dose fashion. Hormone patients will be offered on demand Sildenafil for approximately 15-21 months.

    Hormone therapy patients will complete assessments at baseline (within 4 weeks of start of study treatment) each month (only IIEF and QOL) before start of radiotherapy, at start of radiotherapy and at months 3, 6, 9, 12 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24.

  • Drug: placebo tablets and questionaires

    Non-hormone therapy patients will be instructed to begin the study drug 3 days prior to start of radiotherapy. Patients beginning study drug anytime between 3 days before start of radiotherapy and 2 weeks after the first day of radiotherapy will also be acceptable. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.

    In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand, open label, flexible dose fashion. Non-hormone patients will be offered on demand Sildenafil for approximately 12 months.

    Assessments (IIEF, IPSS, QOL) will be completed by non-hormone therapy patients at baseline (within 4 weeks of start of study treatment) and at approximately months 3, 6, 9, 12, 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24.

  • Active Comparator: 1
    radiotherapy with hormones, questionaire assessments
    Intervention: Drug: sildenafil citrate and questionaires
  • Placebo Comparator: 2
    radiotherapy without hormones, questionaire assessments
    Intervention: Drug: placebo tablets and questionaires
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
290
April 2014
April 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • To receive external beam radiation therapy and/or brachytherapy for biopsy-proven prostate cancer.
  • Baseline International Index of Erectile Function (IIEF) erectile function domain score >= 17.
  • Patients receiving radiotherapy with hormone therapy undergoing a maximum of 9 months of hormone therapy will be acceptable.

Exclusion Criteria:

  • Baseline IIEF-EF (1-30) domain score of <17 pre-therapy
  • Current routine use of erectogenic agents (use of agents > 4 times per month would constitute "routine use")
  • Neoadjuvant androgen deprivation therapy started more than 1 month prior to entry into study (intake of Bicalutamide alone does not constitute exclusion from study entry)
  • Have a clinically significant penile deformity in the opinion of the investigator (ie: Peyronie's Disease)
  • Non-organ confined disease
  • Prior prostate surgery or cryotherapy
  • Prior prostate radiotherapy started more than 2 weeks prior to entry into study
  • Currently taking 0.8mg Flomax daily
  • Penile implant history
  • Present at baseline with chronic angina requiring nitrates, angina occurring during sexual intercourse or unstable angina within the last 6 months.
  • History of myocardial infarction, coronary artery bypass graft surgery or percutaneous coronary intervention within 90 days of baseline visit.
  • History of significant cardiac conduction defect within 90 days of baseline visit.
  • Exhibit systolic blood pressure > 170 or < 90 mm Hg or diastolic blood pressure > 100 or < 50 mm Hg at baseline visit or have a history of malignant hypertension
  • Have any condition that would interfere with the subject's ability to provide informed consent or comply with study instructions, would place subject at increased risk, or might confound the interpretation of the study results
  • Currently receive treatment with nitrates, cancer chemotherapy, or antiandrogens (except finasteride taken as Propecia or Proscar)
  • Have a history of drug, alcohol, or substance abuse within the past 6 months, as assessed by the investigator.
Male
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00142506
05-007
Not Provided
Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
  • Mount Sinai School of Medicine
  • Beth Israel Medical Center
  • St. Luke's-Roosevelt Hospital Center
Principal Investigator: Michael J Zelefsky, M.D. Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP